Reading Scientific Services Ltd (RSSL) is launching a dedicated pharmaceutical consultancy service to help pharmaceutical, biopharmaceutical and advanced therapy organisations navigate increasingly complex quality, regulatory, technical and commercial challenges.
The launch responds to increasing pressure on pharmaceutical, biopharmaceutical and advanced therapy organisations, driven by evolving data integrity expectations, Annex 1 requirements, increasingly globalised supply chains and the rapid development of advanced therapies and personalised medicines. These challenges can be particularly difficult for start-ups, virtual biotechs and smaller contract development and manufacturing organisations (CDMOs) that may lack in-house expertise or capacity in areas such as GMP, regulatory strategy, manufacturing, quality systems and supply chain compliance.
Drawing on RSSL’s more than 30 years of experience supporting the pharmaceutical sector, the consultancy is not purely advisory but science-backed, drawing on RSSL’s GMP and non-GMP laboratories, analytical testing, R&D and training capabilities. The service is delivered by experienced practitioners including Qualified Persons, former inspectors, validation specialists, microbiologists and regulatory experts.
The service spans six core areas:
- Product Development
- CMC
- Quality Systems
- Supply Chain & Distribution
- Regulatory Affairs
- Advanced Therapies & Biotechnology.
This allows RSSL to support clients across the full product lifecycle, from early development to commercial supply and post-approval support.
The consultancy is designed to help clients solve immediate technical, quality and regulatory challenges while building stronger in-house capability. By combining consultancy with training, RSSL aims to support improvements that are embedded for the long term.
Emily Ness, Head of Pharmaceutical Training & Consultancy at RSSL, said:
“Pharmaceutical organisations are operating in an increasingly complex environment, where quality, regulatory and technical challenges can have a direct impact on development timelines, supply continuity and patient access. We aim to give clients access to the specialist expertise they need at the point they need it, while also helping them build the confidence, capability and systems to manage future challenges more independently. By connecting consultancy with laboratory insight, analytical testing, R&D and training, we can help clients move from issue resolution to long-term resilience.”
For more information about RSSL’s pharmaceutical consultancy services, visit the Pharmaceutical Quality, Regulatory and CMC Consultancy page on the RSSL website: https://www.rssl.com/life-science-training-consultancy/pharmaceutical-consultancy/
For media enquiries, please contact:
Charles Ben-Cofie
Editorial Director, Notch Communications
